Funding for this research was provided by:
Wellcome Trust (211182/Z/18/Z)
Article History
Accepted: 24 June 2022
First Online: 26 July 2022
Declarations
:
: James P Sheppard receives funding from the Wellcome Trust/Royal Society via a Sir Henry Dale Fellowship (ref: 211182/Z/18/Z), an National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC) Senior Fellowship and from the British Heart Foundation (refs: PG/21/10341; FS/19/13/34235). Richard J. McManus acknowledges support from the NIHR Applied Research Collaboration (ARC) Oxford Thames Valley and holds an NIHR Senior Investigator award. Grants received by JPS and RJMcM from the NIHR and BHF include funding to undertake randomised controlled trials of antihypertensive deprescribing (including the OPTiMISE, OPTiMISE-X and OPTIMISE2 trials). Athanase Benetos is the chief investigator and National Coordinator of the multicentric French study RETREAT FRAIL. This clinical trial is financed by the National French program of Hospital Clinical Research (PHRC: AOM16549/PHRC-16–0549), by the Agence Nationale de Recherche (ANR) (RHU grant No ANR-15-RHU-0004) and by a special grant from the Agence Régionale de Santé (ARS) Grand Est. This research was funded in part, by the Wellcome Trust [211182/Z/18/Z]. For the purpose of open access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission. The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care.
: This article does not contain any studies with human or animal subjects performed by any of the authors.